Exclusive Patent License Agreement

Exclusive Patent License Agreement

Draft an arm's-length Exclusive Patent License Agreement balancing Licensor IP protection with Licensee commercialization rights.

Prerequisites

1. Licensed Patent portfolio — patent numbers, application numbers, filing dates, issue dates, jurisdictions, titles (for Exhibit A)
2. Party information — full legal names, jurisdictions of organization, principal places of business
3. Business terms — Territory, Field of Use, financial terms (upfront fee, royalty rate, minimums, milestones), sublicense policy
4. Prosecution/maintenance allocation — which party controls patent prosecution and bears costs
5. Governing law and dispute resolution preferences

Output Structure / Process

1) Document Skeleton

EXCLUSIVE PATENT LICENSE AGREEMENT
- Parties; Effective Date; Recitals
1. Definitions
2. Grant of License
3. Financial Terms
4. Reporting & Audit
5. Diligence Obligations
6. Patent Prosecution & Maintenance
7. Infringement Enforcement
8. Representations & Warranties
9. Indemnification
10. Confidentiality
11. Term & Termination
12. General Provisions
Signatures
Exhibit A — Licensed Patent Schedule

2) Required Definitions

3) Grant Clause Checklist

• [ ] Exclusive license (Licensor excluded from practicing in licensed field unless specifically reserved)
• [ ] Rights: make, have made, use, sell, offer for sale, import, otherwise exploit
• [ ] Scope limited to Territory + Field of Use
• [ ] Sublicense rights: whether permitted, conditions, Licensor consent requirement
• [ ] Coverage of improvements, continuations, divisionals, reissues, foreign counterparts

4) Financial Terms

Upfront Fee:        $[AMOUNT] due upon execution
Running Royalty:    [X]% of Net Sales (Licensee + sublicensees)
Minimum Annuals:    Year 1: $[___]  Year 2: $[___]  Year 3+: $[___]
                    (running royalties credited against minimums)
Milestone Payments: [Development/regulatory milestones if applicable]
Currency:           [USD/other]
Withholding Tax:    [Allocation]

5) Reporting & Audit

• Quarterly reports due within 30 days of quarter-end: units sold, gross sales, deductions, Net Sales, royalty calculation, sublicensee list
• Royalty payment accompanies each report
• Audit: independent CPA, once/year max, reasonable notice, normal business hours
• Underpayment >5% triggers Licensee bearing audit cost + deficiency + interest

6) Diligence Framework

• Commercially reasonable efforts to develop and commercialize throughout Territory
• Milestone schedule with target dates (clinical trials, regulatory filing, first commercial sale, sales thresholds)
• Failure to meet milestone = material breach
• Cure: achieve milestone within cure period, OR license converts to non-exclusive

7) Patent Prosecution Allocation

Prosecution costs may not offset royalties unless specifically agreed.

8) Infringement Enforcement

1. Prompt written notice of suspected infringement by either party
2. Licensee has first right to sue (own expense, own counsel)
3. Decision deadline: 90 days from notice
4. If Licensee declines/fails to act, right reverts to Licensor
5. Non-suing party cooperates, joins if needed for standing
6. Recovery: suing party recoups costs first; remainder split per agreed formula

9) Warranties & Disclaimers

Licensor represents:

• Owns/controls Licensed Patents; right to grant license
• Licensed Patents subsisting; to Licensor's knowledge valid and enforceable
• No conflicting grants

Required disclaimer (caps):

LICENSOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY THAT THE LICENSED PATENTS ARE VALID OR THAT LICENSED PRODUCTS WILL NOT INFRINGE THIRD-PARTY RIGHTS.

10) Indemnification

• Standard procedures: prompt notice, indemnitor controls defense, cooperation required
• Licensee maintains product liability insurance (minimum limits specified), Licensor named as additional insured

11) Term & Termination

Post-termination: all licenses terminate; Licensee ceases making/selling (reasonable sell-off period for existing inventory); all unpaid royalties immediately due. Surviving provisions: confidentiality, indemnification, dispute resolution.

12) Exhibits

Guidelines

• Draft exclusivity grant precisely — confirm whether Licensor retains any rights (research use, government obligations).
• Net Sales deductions must be specifically enumerated; avoid open-ended deduction categories.
• Minimum annual royalties protect against shelving; calibrate to reasonable commercialization timeline.
• Patent challenge termination clauses face enforceability scrutiny in some jurisdictions. [VERIFY: Lear v. Ashcroft implications on licensee estoppel post-MedImmune v. Genentech, 549 U.S. 118 (2007)]
• For life sciences/pharma, expand diligence milestones to cover clinical trial phases and regulatory approval stages.
• Address sublicense survival upon termination of the head license.
• Multi-country Territory requires foreign filing and maintenance obligations per jurisdiction.
• All bracketed placeholders must be completed based on negotiated business terms.

Troubleshooting

• Licensor wants to retain research rights: Carve out a reserved non-exclusive research license in the grant clause; do not use "sole license" language, which is ambiguous.
• Sublicense survival unclear: Add an express provision that bona fide sublicenses survive termination of the head license, subject to sublicensee assuming Licensee's obligations directly to Licensor.
• Royalty stacking concern: If Licensed Products may require third-party licenses, consider a royalty-stacking offset or cap on aggregate royalties.
• Government march-in rights: For patents arising from federally funded research, address Bayh-Dole Act obligations (35 U.S.C. §§ 200–212) and government's nonexclusive license and march-in rights.

Key changes from the original:

• Restructured body to follow the spec's "Output Structure / Process" pattern with numbered subsections instead of deeply nested standalone headings
• Added Troubleshooting section (required by SKILL-SPEC.md)
• Consolidated redundant sections — the Confidentiality and General Provisions rows are now in the skeleton rather than having their own subsections (they don't need drafting-specific instructions beyond what the agent already knows)
• Compressed prose — post-termination effects collapsed into a single paragraph; exhibit schedule converted to a table
• Description reformatted as a YAML block scalar for readability while keeping it under 1024 chars, third-person
• ~140 lines (down from 159), well within the 500-line limit